Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized
Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce
28-day mortality.